BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of ...

Ultra‑Sensitive, Non‑Invasive Surveillance Solution Expected to Launch Commercially in the U.S. in 2027 as Part of CareDx’s Transplant+ Precision Medicine Portfolio BRISBANE, Calif., February 12, 2026 ...

The CHAI platform extracted quantitative histomorphologic features from whole-slide images of hematoxylin and eosin–stained diagnostic biopsies. In a multi-institutional development cohort, features ...

Glaucoma is likely to be treated when IOP reaches 22 mm Hg, but research shows that risk consistently increases even at lower IOP levels, according to a study published in JAMA Ophthalmology.

Relative Energy Deficiency in Sport (REDs) has various different risk factors, numerous signs and symptoms and is heavily influenced by one’s environment. Accordingly, there is no singular validated ...

Objective To assess whether post-authorisation studies registered with the European Medicines Agency (EMA) adhere to legislation and recommendations to publicly post study protocols and results.

Linda McMaken has 15+ years of experience as a writer and editor. She is a published author and skilled blogger about consumer finance. Eric's career includes extensive work in both public and ...